Marksans Pharma Ltd
NSE:MARKSANS
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Estee Lauder Companies Inc
NYSE:EL
|
Consumer products
|
| US |
|
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
| US |
|
Church & Dwight Co Inc
NYSE:CHD
|
Consumer products
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
American Express Co
NYSE:AXP
|
Financial Services
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Target Corp
NYSE:TGT
|
Retail
|
| US |
|
Walt Disney Co
NYSE:DIS
|
Media
|
| US |
|
Mueller Industries Inc
NYSE:MLI
|
Machinery
|
| US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
Technology
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
132.95
318.35
|
| Price Target |
|
We'll email you a reminder when the closing price reaches INR.
Choose the stock you wish to monitor with a price alert.
|
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
|
Estee Lauder Companies Inc
NYSE:EL
|
US |
|
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
|
Church & Dwight Co Inc
NYSE:CHD
|
US |
|
|
Pfizer Inc
NYSE:PFE
|
US |
|
|
American Express Co
NYSE:AXP
|
US |
|
|
Nike Inc
NYSE:NKE
|
US |
|
|
Visa Inc
NYSE:V
|
US |
|
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
|
3M Co
NYSE:MMM
|
US |
|
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
|
Coca-Cola Co
NYSE:KO
|
US |
|
|
Target Corp
NYSE:TGT
|
US |
|
|
Walt Disney Co
NYSE:DIS
|
US |
|
|
Mueller Industries Inc
NYSE:MLI
|
US |
|
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
This alert will be permanently deleted.
Marksans Pharma Ltd
Marksans Pharma Ltd
Cash & Cash Equivalents
Marksans Pharma Ltd
Cash & Cash Equivalents Peer Comparison
DRREDDY
CIPLA
SUNPHARMA
Competitive Cash & Cash Equivalents Analysis
Latest Figures & CAGR of Competitors
| Company | Cash & Cash Equivalents | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
|
|
Marksans Pharma Ltd
NSE:MARKSANS
|
Cash & Cash Equivalents
₹6.7B
|
CAGR 3-Years
47%
|
CAGR 5-Years
82%
|
CAGR 10-Years
31%
|
|
|
Dr Reddy's Laboratories Ltd
NSE:DRREDDY
|
Cash & Cash Equivalents
₹7.1B
|
CAGR 3-Years
-22%
|
CAGR 5-Years
26%
|
CAGR 10-Years
N/A
|
|
|
Cipla Ltd
NSE:CIPLA
|
Cash & Cash Equivalents
₹9.2B
|
CAGR 3-Years
-14%
|
CAGR 5-Years
-4%
|
CAGR 10-Years
16%
|
|
|
Sun Pharmaceutical Industries Ltd
NSE:SUNPHARMA
|
Cash & Cash Equivalents
₹90.2B
|
CAGR 3-Years
7%
|
CAGR 5-Years
6%
|
CAGR 10-Years
4%
|
|
T
|
Torrent Pharmaceuticals Ltd
NSE:TORNTPHARM
|
Cash & Cash Equivalents
₹11.5B
|
CAGR 3-Years
49%
|
CAGR 5-Years
14%
|
CAGR 10-Years
7%
|
|
M
|
Mankind Pharma Ltd
NSE:MANKIND
|
Cash & Cash Equivalents
₹1.2B
|
CAGR 3-Years
-45%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
See Also
What is Marksans Pharma Ltd's Cash & Cash Equivalents?
Cash & Cash Equivalents
6.7B
INR
Based on the financial report for Jun 30, 2024, Marksans Pharma Ltd's Cash & Cash Equivalents amounts to 6.7B INR.
What is Marksans Pharma Ltd's Cash & Cash Equivalents growth rate?
Cash & Cash Equivalents CAGR 10Y
31%
Over the last year, the Cash & Cash Equivalents growth was -6%. The average annual Cash & Cash Equivalents growth rates for Marksans Pharma Ltd have been 47% over the past three years , 82% over the past five years , and 31% over the past ten years .
You don't have any saved screeners yet
